How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/urethritis-due-to-chlamydia-trachomatis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Urethritis due to Chlamydia trachomatis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Urethritis due to Chlamydia trachomatis (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Urethritis due to Chlamydia trachomatis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tomefloxacin	GREPAFLOXACIN	Otsuka	grepafloxacin	Potassium voltage-gated channel subfamily H member 2	1997-01-01
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Azo Gantrisin	sulfafurazole	Alra	Sulfonamide Antimicrobial	Endothelin-1 receptor	1971-01-01
Benzamycin	Erythromycin Lactobionate	Pfizer	Macrolide	Potassium voltage-gated channel subfamily H member 2	1964-01-01
E-Mycin	erythromycin	Generic (originally Abbott/Lilly)	Macrolide [EPC]	Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1	1952-01-01
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Urethritis due to Chlamydia trachomatis
Alra · 1 drug in Urethritis due to Chlamydia trachomatis
Assistance Publique - Hôpitaux de Paris · 1 drug in Urethritis due to Chlamydia trachomatis
Generic (originally Abbott/Lilly) · 1 drug in Urethritis due to Chlamydia trachomatis
Otsuka · 1 drug in Urethritis due to Chlamydia trachomatis
Pfizer · 1 drug in Urethritis due to Chlamydia trachomatis
Pfizer Inc. · 1 drug in Urethritis due to Chlamydia trachomatis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Urethritis due to Chlamydia trachomatis:

Cite this brief

Drug Landscape (2026). Urethritis due to Chlamydia trachomatis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/urethritis-due-to-chlamydia-trachomatis. Accessed 2026-06-10.

Urethritis due to Chlamydia trachomatis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing